Table 3.
Cox proportional-hazard regression analysis for clinical characteristics and overall survival in TCGA patients
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| UTRN (low vs. high) | 0.62 | 0.47–0.81 | < 0.001 | 0.51 | 0.34–0.78 | 0.002 |
| T (T1T2 vs. T3T4) | 2.00 | 1.44–2.77 | < 0.001 | 0.78 | 0.46–1.34 | 0.37 |
| N (N0 vs. N1N2) | 1.59 | 1.15–2.19 | 0.01 | 1.73 | 0.52–5.76 | 0.38 |
| M (M0 vs. M1) | 1.74 | 0.92–3.30 | 0.09 | – | – | – |
| Stage (stage1/2 vs. stage3/4) | 1.64 | 1.22–2.20 | < 0.001 | 1.06 | 0.32–3.51 | 0.93 |
| Clark level (I/II/III vs. IV/V) | 2.09 | 1.47–2.98 | < 0.001 | 1.26 | 0.75–2.12 | 0.38 |
| Age (< 60 vs. ≥ 60) | 1.59 | 1.20–2.09 | 0.001 | 1.77 | 1.12–2.81 | 0.02 |
| Ulceration (no vs. yes) | 2.08 | 1.49–2.91 | < 0.001 | 1.67 | 1.05–2.66 | 0.03 |
| New tumor event (no vs. yes) | 0.75 | 0.51–1.09 | 0.13 | – | – | – |
| Cancer status (tumor free vs. with tumor) | 4.27 | 3.00–6.07 | < 0.001 | 5.82 | 3.32–10.21 | < 0.001 |
| Race (Asian vs. White) | 0.22 | 0.10–0.48 | < 0.001 | 0.55 | 0.07–4.17 | 0.56 |
The univariate analysis presented impact of UTRN expression, T stage, N stage, M stage, clinical stage, Clark level, age, ulceration, new tumor event, cancer status and race on overall survival in melanoma. Additionally, the multivariate analysis demonstrated the significance of the effect of UTRN expression, age, ulceration and cancer status on overall survival in melanoma